A new study has found that an inactivation of intestinal probiotics reduces the risk of cardiovascular disease and type 2 diabetes

recently, a new Belgian study found that taking an inactivate intestinal probiotic improves metabolism and reduces the risk of cardiovascular disease and type 2 diabetes from obesity.The bacteria, called mucosal protein Ackermann's bacteria, is one of the main members of the human gut bacterium and was first isolated and identified in 2004. Previous animal experiments have shown that it has the effect of suppressing metabolic diseases such as type 2 diabetes, and that the bacteria is even better at reducing the risk of cardiovascular disease after inactivation than live bacteria.In a paper published in the British journal Nature Medicine, the team said 32 overweight or obese volunteers completed the trial.The volunteers were divided into three groups of daily oral live mucosal Ackman bacteria, the bacteria or placebo inactivated by pasteurization, without changing their diet and exercise habits.The results showed that volunteers who took inactivation bacteria after three months were more sensitive to insulin and had lower plasma cholesterol levels, meaning they had a lower risk of cardiovascular disease and type 2 diabetes. These indicators continued to worsen in the volunteers who took the placebo.Inactivation bacteria also caused a small drop in the volunteers' weight, body fat and hip circumference, and lowered levels of some inflammatory markers in the liver.In the experiment, the volunteers were given 10 billion live or inactived bacteria per day, and after three months of continuous use, no side effects were shown, and the safety and tolerance were good.The researchers say this suggests that using the bacteria as a dietary supplement is feasible. (Drug Information Network)